Navelbine

Indicated For

NSCLC, breast cancer

About This Medication

# Navelbine Patient Assistance Program Guide: How to Get Vinorelbine at Low Cost ## About This Program Navelbine (vinorelbine) is a chemotherapy medication used to treat lung cancer and, in some cases, advanced breast cancer. If you're struggling to afford this important medication, patient assistance programs can help you access it at significantly reduced costs. ## What is Navelbine? Vinorelbine, sold under the brand name Navelbine, is a chemotherapy drug derived from the periwinkle plant. It works by slowing the growth of cancer cells and is primarily used to treat locally advanced or metastatic non-small cell lung cancer (NSCLC). The medication is administered as an intravenous injection, typically at a dose of 30 mg per square meter of body surface area, given weekly over 6-10 minutes.[8] ## Program Overview Multiple patient assistance options are available for Navelbine, depending on your insurance status and financial situation:[1][2][4] - **Prescription Hope Program**: Offers Navelbine for $70 per month through their patient assistance program[1] - **Pfizer Oncology Co-Pay Assistance**: For eligible commercially insured patients, may reduce out-of-pocket costs to as little as $0 per treatment, with potential annual savings of $4,000–$25,000[4] - **General Patient Assistance Programs**: Various pharmaceutical companies and specialty pharmacies offer assistance for patients who cannot afford their medications[6] ## Who Qualifies? Eligibility varies by program but generally includes: - **Uninsured patients**: Those without any health insurance coverage[2] - **Low-income patients**: Individuals and families with limited financial resources[2] - **Underinsured patients**: Those whose insurance doesn't adequately cover Navelbine[2] - **Commercially insured patients**: For co-pay assistance programs (with restrictions noted below)[4] ## Income Eligibility While specific income thresholds for Navelbine assistance programs are not detailed in available sources, patient assistance programs generally serve individuals and families with limited financial resources. Income limits typically align with federal poverty guidelines, though exact thresholds vary by program. **Important Insurance Restriction**: Patients enrolled in state or federally funded insurance programs—including Medicare, Medicaid, TRICARE, Veterans Affairs health care, state prescription drug assistance programs, or Puerto Rico's Government Health Insurance Plan—are **not eligible** for Pfizer Oncology's co-pay assistance card.[4] ## Insurance Requirements Different programs have different insurance requirements: - **Prescription Hope**: Serves uninsured and underinsured patients[1] - **Pfizer Co-Pay Assistance**: Designed for commercially insured patients only; federal insurance recipients are excluded[4] - **General PAPs**: Available to uninsured consumers and those with low incomes[2] If you have Medicare or Medicaid, you may still qualify for other assistance programs, but you cannot use Pfizer's co-pay card. Discuss alternative options with your healthcare provider or oncology social worker. ## How to Apply ### Step 1: Determine Your Program Work with your oncology team, social worker, or pharmacist to identify which assistance program best fits your situation. Consider your insurance status, income level, and medication needs. ### Step 2: Gather Required Information Have the following information ready: - Your prescription from your oncologist - Proof of income (recent tax return, pay stubs, or benefit statements) - Insurance information (if applicable) - Identification and contact information ### Step 3: Contact the Program **Prescription Hope**: Visit their website or call to enroll and get pre-qualified for the $70/month program[1] **Pfizer Oncology**: Contact Pfizer Oncology Together for co-pay assistance eligibility and enrollment[4] **Other Programs**: Ask your healthcare provider for referrals to additional pharmaceutical assistance programs specific to your situation[6] ### Step 4: Submit Your Application Complete the application through the program's website, phone, or mail. Provide all requested documentation to support your eligibility. ### Step 5: Await Approval Program staff will review your application and contact you with approval status and next steps. ## Timeline and Delivery Processing times vary by program. Once approved, medications are typically delivered directly to your home or to your pharmacy, depending on the program's delivery method. Confirm delivery details with your program coordinator. ## What If Your Application Is Denied? If you're denied assistance: 1. Ask the program why you were denied and what information might help 2. Explore alternative programs—multiple options exist for Navelbine assistance 3. Contact your oncology social worker for additional resources 4. Ask your healthcare provider about generic alternatives or other treatment options 5. Inquire about hospital financial assistance programs ## Important Considerations **Side Effects**: Common side effects of Navelbine include nausea, weakness, constipation, injection site pain, peripheral neuropathy, vomiting, diarrhea, hair loss, blood clots, and shortness of breath.[8] Discuss any side effects with your healthcare team. **Prior Authorization**: Your insurance company may require prior authorization before covering Navelbine, even with assistance programs.[8] **Reauthorization**: Some programs may require periodic reauthorization to continue receiving assistance. Your program coordinator will inform you of any renewal requirements. ## Disclaimer This guide provides general information about patient assistance programs for Navelbine. Program details, eligibility requirements, and benefits change frequently. Always verify current program information directly with the assistance program provider or your healthcare team. This information is not a substitute for professional medical or financial advice. Consult your oncologist and social worker for personalized guidance on accessing Navelbine.

Program information last verified: March 30, 2026